Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Itameline

From Wikipedia, the free encyclopedia
Muscarinic agonist

Pharmaceutical compound
Itameline
Clinical data
Other namesRU-47213; RU47213
Drug classNon-selectivemuscarinic acetylcholine receptor agonist
Identifiers
  • (4-chlorophenyl) 5-[(E)-methoxyiminomethyl]-3,6-dihydro-2H-pyridine-1-carboxylate
CAS Number
PubChemCID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC14H15ClN2O3
Molar mass294.74 g·mol−1
3D model (JSmol)
  • CO/N=C/C1=CCCN(C1)C(=O)OC2=CC=C(C=C2)Cl
  • InChI=1S/C14H15ClN2O3/c1-19-16-9-11-3-2-8-17(10-11)14(18)20-13-6-4-12(15)5-7-13/h3-7,9H,2,8,10H2,1H3/b16-9+
  • Key:CTVQNEVLCGSTKL-CXUHLZMHSA-N

Itameline (INNTooltip International Nonproprietary Name; developmental code nameRU-47213) is anon-selectivemuscarinic acetylcholine receptoragonist which was under development for the treatment ofAlzheimer's disease andmemory disorders but was never marketed.[1][2][3] It has been referred to as a "nootropic" (cognitive enhancer).[4][5]

The drug is aprodrug ofRU-35963, anarecolinederivative.[6][7][2] It is an agonist of the muscarinic acetylcholineM1 receptor as well as of other muscarinic acetylcholine receptors.[8][6][9][7][2] Itameline is described as being superior to arecoline in terms ofpotency,centralselectivity, andduration of action.[6][7] The drug showsantiamnesic effects in animals, for instance reversingscopolamine-inducedmemory deficits.[10][6][2][3]Structurally, it is atetrahydropyridine similarly toxanomeline andmilameline.[11]

Itameline was first described in thescientific literature by 1992.[3] It was under development byHoechst Marion Roussel and reachedphase 2clinical trials by 1998 prior to the discontinuation of its development.[12][7][4]

References

[edit]
  1. ^"Delving into the Latest Updates on Itameline with Synapse".Synapse. 28 September 2024. Retrieved26 October 2024.
  2. ^abcdM'Harzi M, Willig F, Gieules C, Palou AM, Oberlander C, Barzaghi F (April 1997). "Ameliorating effects of RU 47213, a novel oral and long-lasting cholinomimetic agent, on working memory impairments in rats".Pharmacology, Biochemistry, and Behavior.56 (4):663–668.doi:10.1016/s0091-3057(96)00423-6.PMID 9130292.
  3. ^abcToja E, Bonetti C, Butti A, Hunt P, Fortin M, Barzaghi F, et al. (1992). "1-substituted-1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-alkyloximes as novel orally active and long-lasting muscarinic cholinergic agonists".European Journal of Medicinal Chemistry.27 (5). Elsevier BV:519–526.doi:10.1016/0223-5234(92)90186-5.ISSN 0223-5234.
  4. ^abFroestl W, Muhs A, Pfeifer A (2012). "Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors".Journal of Alzheimer's Disease.32 (4):793–887.doi:10.3233/JAD-2012-121186.PMID 22886028.
  5. ^Fischer F, Matthisson M, Herrling P (2004). "List of drugs in development for neurodegenerative diseases".Neuro-Degenerative Diseases.1 (1):50–70.doi:10.1159/000077879.PMID 16908974.
  6. ^abcdCamps P, Muñoz-Torrero D (February 2002). "Cholinergic drugs in pharmacotherapy of Alzheimer's disease".Mini Reviews in Medicinal Chemistry.2 (1):11–25.doi:10.2174/1389557023406638.PMID 12369954.
  7. ^abcdSaklani A, Kutty SK (February 2008). "Plant-derived compounds in clinical trials".Drug Discovery Today.13 (3–4):161–171.doi:10.1016/j.drudis.2007.10.010.PMID 18275914.
  8. ^Palma JA (February 2024)."Muscarinic control of cardiovascular function in humans: a review of current clinical evidence".Clinical Autonomic Research.34 (1):31–44.doi:10.1007/s10286-024-01016-5.PMC 10994193.PMID 38305989.
  9. ^Korczyn AD (October 2000). "Muscarinic M(1) agonists in the treatment of Alzheimer's disease".Expert Opinion on Investigational Drugs.9 (10):2259–2267.doi:10.1517/13543784.9.10.2259.PMID 11060805.
  10. ^Deiana S, Platt B, Riedel G (August 2011). "The cholinergic system and spatial learning".Behavioural Brain Research.221 (2):389–411.doi:10.1016/j.bbr.2010.11.036.PMID 21108971.
  11. ^Mirza NR, Peters D, Sparks RG (2003)."Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists".CNS Drug Reviews.9 (2):159–186.doi:10.1111/j.1527-3458.2003.tb00247.x.PMC 6741650.PMID 12847557.
  12. ^Eglen RM, Hegde SS (1998). "Selective modulation of muscarinic receptor subtypes: therapeutic potential".Emerging Drugs.3 (1). Informa Healthcare:67–80.doi:10.1517/14728214.3.1.67.ISSN 1361-9195.
mAChRsTooltip Muscarinic acetylcholine receptors
Agonists
Antagonists
Precursors
(andprodrugs)
Stub icon

Thispharmacology-related article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Itameline&oldid=1253845776"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp